Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

ACR Issues Guidelines, Recommendations for Lupus Nephritis, RA

Kathy Holliman  |  Issue: June 2012  |  June 10, 2012

Two expert panels developed the recommendations. A nonvoting working group and core expert panel of clinicians and methodologists selected the topic areas, conducted the literature review, synthesized the evidence, and created clinical scenarios that represented the spectrum of care to be addressed by the guideline. A task force panel of 11 internationally recognized expert clinicians, patient representatives, and methodologists with expertise in RA treatment rated the scenarios and provided formal input about recommendations.

[The RA treatment recommendations] provide guidance for practitioners who will still make individual decisions with their patients depending on their patients’ preferences and risk factors and other disease factors.

—Jasvinder Singh, MBBS, MPH

Most important in these recommendations is the specific guidance about when to start, resume, add, or switch DMARD therapy or biologic agents, and how to switch between various biologic agents, says Dr. Singh. The updated recommendations also provide guidance on using biologic agents when the patient has a diagnosis of hepatitis, malignancy, or congestive heart failure. Other key points included in the document:

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE
  • Tuberculosis (TB) screening to identify latent TB infection should be done in all patients with RA who are being considered for therapy with biologic agents, regardless of the presence of risk factors for latent TB.
  • Specific recommendations for vaccinations, including the pneumococcal, influenza, hepatitis B, human papillomavirus, and herpes zoster vaccines, are given for patients starting or currently receiving DMARDs or biologic agents.
  • New biologics launched since the 2008 recommendations—tocilizumab, certolizumab pegol, and golimumab—are included in the treatment algorithm.

More aggressive treatment is advised for patients with early RA in this document compared with the 2008 recommendations. This type of recommendation is given due to an expectation that earlier treatment can lead to better outcomes, that prevention of joint damage is an important goal, and that early intensive therapy can help preserve physical function and improve quality of life. Dr. Singh notes that the illustrative figures included in the 2012 recommendations can provide the practitioner with “more elaborative information than that achieved in the text itself,” with details given about treatment regimens and switching between therapies. We “provide guidance for practitioners who will still make individual decisions with their patients depending on their patients’ preferences and risk factors and other disease factors that may make them choose one medication over another,” he says.

Choosing Disease Activity Measures

Rheumatoid Arthritis Disease Activity Measures: American College of Rheumatology Recommendations for Use in Clinical Practice highlights six disease-activity measures that are feasible to perform in a clinical setting; give a real-time score rather than a relative change measure; have defined ranges for low, moderate, and high disease activity; and include remission criteria.5 This document “acknowledges that you should measure disease activity in a formal fashion rather than as a gestalt,” Dr. Kazi says.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Page: 1 2 3 4 5 | Single Page
Share: 

Filed under:Biologics/DMARDsClinical Criteria/GuidelinesConditionsDrug UpdatesFrom the CollegeRheumatoid ArthritisSystemic Lupus Erythematosus Tagged with:AC&RAmerican College of Rheumatology (ACR)BiologicsdrugGlucocorticoidsGuidelinesLupusLupus nephritispatient careRheumatoid arthritisSystemic lupus erythematosustocilizumab

Related Articles

    Lupus Classification Criteria Expanded; Treat-to-Target Approach Gains Support

    July 1, 2014

    Rheumatologists at the California Rheumatology Alliance 10th Annual Medical & Scientific Meeting in San Francisco outline disease classification criteria, treat-to-target approach to lupus

    Combining Humanities, Clinical Care Essential to Providing Quality Healthcare

    February 15, 2017

    WASHINGTON, D.C.—Paulette Hahn, MD, associate professor of medicine specializing in rheumatology at the University of Florida (UF), said she once treated a patient named Monica, a UF undergraduate who had severe inflammatory muscle disease and severe lung disease. The patient’s disease was under control for the time being, but Monica knew she could take a…

    Lupus Nephritis Guidelines in Progress

    April 13, 2011

    A preview of the upcoming recommendations

    Trailblazers in Rheumatology

    July 26, 2023

    We were sad to learn that Rodanthi C. Kitridou, MD, MACR, passed away July 6, 2023, after a long illness. Dr. Kitridou was the longtime director of clinical rheumatology at at LAC/USC Medical Center in Los Angeles.

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences